Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer study findings have been reported from University of California
March 5th, 2009
According to recent research from the United States, "Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors. After a 1-week, three-dose course of thalidomide, the mean MRI-assayed endothelial transfer coefficient, K-PS, decreased significantly (p < 0.05) from 19.4 +/- 9.1 to 6.3 +/- 9.1 mu l/min center dot 100 cm(3)." "Correspondingly, microscopic measurements of extravasated MMCM, expressed as fractional area of streptavidin staining, were...
Source: Women's Health Weekly (2009-03-05)
|
